Entanercept;1-235-TuMor necrosisfactor receptor (huMan) fusion protein with 236-467-iMMunoglobulin G1 (huMan g1-chain Fc fragMent) (9CI);TNFR-Fc fusion protein;Etanercept;Embrel;Enbrel;rhuTNFR: Fc;rhu-TNFR-Fc
用途
Etanercept is approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and juvenile idiopathic arthritis (JIA). It is effective in managing these rheumatic diseases by inhibiting tumor necrosis factor (TNF) activity, thereby controlling inflammation and halting disease progression. In patients with hip joint involvement due to RA, JIA, PsA, or AS, etanercept is recommended to be used in combination with methotrexate; however, the benefit of combining it with methotrexate in purely axial AS remains controversial. Etanercept is also effective in the treatment of plaque psoriasis.